Form 4: DexCom Director Nicholas Augustinos Reports Changes in Beneficial Ownership

Nicholas Augustinos, a director at DexCom Inc., reported a transfer of shares to a revocable trust and the grant of restricted stock units.

Summary

• On May 8, 2025, Nicholas Augustinos, a director of DexCom Inc., reported changes in his beneficial ownership of DexCom common stock.
• He transferred 2,618 shares from direct ownership to the Kirschner/Augustinos Revocable Trust.
• He also received a grant of 5,046 restricted stock units (RSUs).
• These RSUs will vest on the earlier of May 8, 2026, or the date of DexCom's 2026 Annual Meeting of Stockholders.
• Following these transactions, Augustinos directly owns 5,046 shares and indirectly owns 39,701 shares through the Kirschner/Augustinos Revocable Trust.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting standard compensation practices. It doesn't inherently indicate positive or negative sentiment.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.

Future Outlook

The RSUs will vest on the earlier of May 8, 2026, or the date of DexCom's 2026 Annual Meeting of Stockholders, representing a contingent right to receive DexCom common stock.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a DexCom director.

Stakeholder Impact

• The RSU grant aligns the director's interests with shareholders, potentially incentivizing value creation.

Key Dates

Keywords

DexCom, Nicholas Augustinos, beneficial ownership, Form 4, RSU, restricted stock units, director, securities, trust